Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma

Li-Juan Wang; Kai-Liang Zhang; Ning Zhang; Xiang-Wei Ma; Su-Wen Yan; Dong-Hua Cao; Sheng-Jia Shi

doi:10.18632/oncotarget.4072

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma

Li-Juan Wang _, Kai-Liang Zhang, Ning Zhang, Xiang-Wei Ma, Su-Wen Yan, Dong-Hua Cao and Sheng-Jia Shi

PDF | HTML | How to cite

Oncotarget. 2015; 6:18631-18640. https://doi.org/10.18632/oncotarget.4072

Metrics: PDF 1895 views | HTML 2390 views | ?

Abstract

Li-Juan Wang1,*, Kai-Liang Zhang2,*, Ning Zhang3,*, Xiang-Wei Ma3, Su-Wen Yan3, Dong-Hua Cao3, Sheng-Jia Shi3

1Department of Oncology, The First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi’an, 710061, Shaanxi Province, P.R. China

2Deparment of Orthopedics, No. 88 Hospital of PLA, Tai’an, 271000, Shandong Province, P.R. China

3Deparment of Aristogenesis, No. 202 Hospital of PLA, Shenyang, 110003, Liaoning Province, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Sheng-Jia Shi, e-mail: [email protected]

Dong-Hua Cao, e-mail: [email protected]

Keywords: serum miR-26a, diagnostic, prognosis, cholangiocarcinoma

Received: February 26, 2015 Accepted: May 18, 2015 Published: May 29, 2015

ABSTRACT

In order to determine the diagnostic and prognostic value of miR-26a in Cholangiocarcinoma (CCA), we compared miR-26a levels in serum from 66 CCA patients and 66 healthy controls, which was followed by serum analysis between the pre-operative serum and post-operative serum of these CCA patients. We found the concentration levels of miR-26a in serum of CCA patients were significantly higher than that from healthy controls (P < 0.01). Furthermore, the concentration levels of miR-26a in the post-operative serum were significantly reduced when compared to the pre-operative serum (P < 0.001). High miR-26a in serum was correlated significantly with clinical stage, distant metastasis, differentiation status, and poor survival of CCA patients. More importantly, serum miR-26a was an independent prognostic marker for CCA. In conclusion, our results suggested that miR-26a in serum might be a potential and useful noninvasive biomarker for the early detection of CCA.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4072

Publication Alerts

Research Papers:

Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma

Abstract